Investor Relations

(Security Code :4506 TSE Prime)

Pick Up

Jun. 06, 2025	Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo’s Canadian Portfolio（PDF/175KB）	Corporate
May 30, 2025	Sumitomo Pharma and Novo Nordisk Pharma Enter into a Co-Promotion Agreement for Ozempic Subcutaneous Injection, a Treatment for Type 2 Diabetes, in Japan	Licensing
May 28, 2025	(Progress of disclosure matters) Notice Regarding a Company Split (Simplified Absorption-Type Company Split) of the Asian Business and the Execution of a Share Transfer Agreement and a Shareholders' Agreement with Marubeni Global Pharma Corporation	Corporate
May 19, 2025	Posted conference on FY2024 Financial Results and Reboot 2027 – Reboot for a Strong Sumitomo Pharma – [Webcast]	Finances
May 13, 2025	Presentation Material (Conference on FY2024 Financial Results and Reboot 2027 – Reboot for a Strong Sumitomo Pharma –)（PDF/4,377KB）	Finances
May 13, 2025	Supplementary Financial Data (IFRS) for the Year Ended March 31, 2025（PDF/500KB）	Finances

Jul. 31, 2025	1st Quarter of FY2025 financial results announcement (planned, 3:30 p.m.)
Jun. 26, 2025	205th Annual Shareholders’ Meeting